Effect of interleukin-2 on biodistribution of monoclonal antibody in tumor and normal tissues in mice bearing SL-2 thymoma

Journal of the National Cancer Institute

Volumn 84, Issue 2, 1992, Pages 109-113

  Schultz, Kirk R ^a   Badger, Christopher C ^b   Dombi, George W ^c   Greenberg, Philip D ^d   Bernstein, Irwin D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d University of Washington and Department of Pediatrics and Department of Medical Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN; CAPILLARY PERMEABILITY; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LUNG; LYMPH NODE; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIODINATION; SPLEEN; T CELL LYMPHOMA; THYMOMA; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; TUMOR DIFFERENTIATION;

ALBUMINS; ANIMAL; ANTIBODIES, MONOCLONAL; INTERLEUKIN-2; ISOANTIBODIES; LYMPHOMA, T-CELL; MICE; MICE, INBRED AKR; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THYMOMA; TISSUE DISTRIBUTION;

EID: 0026599835     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.2.109     Document Type: Article

References (17)

1. Berinstein N. Levy R: Treatment of a murine B cell lymphoma with monoclonal antibodies and IL-2. J Immunol 139:971-976. 1987
2. Berinstein N. Starnes CO. Levy R: Specific enhancement of the therapeutic effect of antiidiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 140:2839-2845. 1988
3. Schultz KR, Klarnet JP, Peace DJ. et al: Monoclonal antibody therapy of murine lymphoma: Enhanced efficacy by concurrent administration of interleukin 2 or lymphokine- activated killer cells. Cancer Res 50:5421-5425.1990
4. Press OW, Eary JF, Badger CC. et al: Treatment of refractory non-Hodgkin s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027-1038. 1989
5. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137:1735-1742, 1986
6. Damle NK. Doyle LV. Bender JR. et al: Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 138:1779-1785,1987
7. Sculier JP, Body JJ, Nejai S, et al: Endogenous production of tumor necrosis factor- alpha in cancer patients during adoptive immunotherapy with interleukin-2 (IL-2). Proc AACR 29:4093, 1988
8. Lotze MT. Matory YL. Ettinghausen SE. et al: In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135:2865-2876, 1985
9. Badger CC, Krohn KA, Peterson AV, et al: Experimental radiotherapy of murine lymphoma with l3lI-labeled anti-Thy 1.1 monoclonal antibody. Cancer Res 45:1536-1544, 1985
10. Nowinski RC, Hays EF, Doyle T, et al: Oncornaviruses produced by murine leukemia cells in culture. Virology 81:363-370, 1977
11. Denkers EY, Badger CC, Ledbetter JA, et al: Influence of antibody isotype on the passive serotherapy of lymphoma. J Immunol 135:2183-2186,1985
12. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
13. Colton T, ed: Statistics in Medicine. Boston: Little, Brown, 1974
14. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492,1985
15. Grimm EA, Mazumder A, Zhang HS. et al: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823-1841, 1982
16. Peace DJ, Cheever MA: Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 169:161-173.1989
17. Ortaldo JR, Mason A. Overton R: Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 164:1193-1205.1986